China hits Swiss pharma company with RPM fine
China’s antitrust authority has fined the local subsidiary of Swiss pharmaceutical company Geistlich Pharma €1.3 million for dictating resale prices for a pair of products used in dental implants over a 12-year period.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.